<!DOCTYPE html>
<html>
  <head>
    <title>Type 2 diabetes mellitus</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta charset="utf-8">
    <!-- Bootstrap -->
    <link href="//netdna.bootstrapcdn.com/bootswatch/3.2.0/flatly/bootstrap.min.css" rel="stylesheet" media="screen">
    <link href="/css/site.css" rel="stylesheet" media="screen">
    <link href="/css/syntax.css" rel="stylesheet" media="screen">

    <!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
    <!--[if lt IE 9]>
      <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
      <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->
<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-48968311-4', 'jandecaluwe.com');
  ga('send', 'pageview');

</script>
  </head>

  <body>

    <!-- Fixed navbar -->
    <div class="navbar navbar-default navbar-fixed-top">
      <div class="container">
        <div class="navbar-header">
          <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </button>
          <a class="navbar-brand" href="/">Rory’s notes</a>
        </div>
        <div class="navbar-collapse collapse">

          <ul class="nav navbar-nav navbar-left">
 
          </ul>

          <ul class="nav navbar-nav navbar-right">
            <li class="active"><a href="/notes/">notes</a></li>
          </ul>

        </div><!--/.nav-collapse -->
      </div>
    </div>


<div class="container">

  <ol class="breadcrumb">
    <li><a href="/">Home</a></li>
      <li><a href="/notes/">notes</a></li>
      <li><a href="/notes/endocrine/">endocrine</a></li>
      <li class="active">Type 2 diabetes mellitus</li>
  </ol>

  <div class="page-header">
 
    <h1>Type 2 diabetes mellitus</h1>
  </div>

  <div class="row">

    <div class="col-md-3" role="navigation"> 
 
      <div class="sidebar" data-spy="affix" data-offset-top="80" data-offset-bottom="60">
        <div class="well">
          <a href="#"><strong>Type 2 diabetes mellitus</strong></a>
          <div class="toc">
<ul>
<li><a href="#diagnosis">diagnosis</a><ul>
<li><a href="#screening">Screening</a></li>
</ul>
</li>
<li><a href="#management">management</a><ul>
<li><a href="#determining-level-of-risk-for-dm-complications">Determining level of risk for DM complications</a></li>
<li><a href="#goals">Goals;</a></li>
<li><a href="#lifestyle">Lifestyle</a></li>
<li><a href="#metformin">Metformin</a></li>
<li><a href="#sulfonylurea">sulfonylurea</a></li>
<li><a href="#insulin">Insulin</a><ul>
<li><a href="#analogues-of-insulin">analogues of insulin:</a></li>
</ul>
</li>
<li><a href="#acarbose">Acarbose</a></li>
<li><a href="#glitazones-pioglitazone">Glitazones (pioglitazone)</a></li>
<li><a href="#glp-1-glucagon-like-peptide-1-agonists">GLP-1 (glucagon-like peptide 1) agonists</a></li>
<li><a href="#surgical-intervention">Surgical intervention</a></li>
</ul>
</li>
<li><a href="#complications">Complications</a><ul>
<li><a href="#diabetic-peripheral-neuropathy">diabetic peripheral neuropathy</a></li>
<li><a href="#hypertension">Hypertension</a></li>
<li><a href="#renal-disease">Renal disease</a></li>
<li><a href="#diabetic-retinopathy">Diabetic retinopathy</a></li>
</ul>
</li>
<li><a href="#hypoglycaemia">Hypoglycaemia</a></li>
<li><a href="#referral">referral</a></li>
<li><a href="#follow-up">follow - up</a></li>
<li><a href="#poor-glycaemic-control-hba1c-6264mmolmol">Poor glycaemic control HbA1c >64mmol/mol</a></li>
<li><a href="#intermediate-hyperglycaemia">Intermediate hyperglycaemia</a><ul>
<li><a href="#management_1">management</a></li>
</ul>
</li>
</ul>
</div>

        </div>
      </div>
    </div>
 
    <div class="content">
      <div class="col-md-6" role="main">
        <blockquote>
<p>thrshold where prevalence of moderate diabetic retinopathy begins to increase exponentially</p>
</blockquote>
<h3 id="diagnosis">diagnosis</h3>
<ul>
<li>
<p>HbA1c = recommended diagnostic test</p>
<ul>
<li>
<p>≥ 50 with symptoms: DM</p>
</li>
<li>
<p>≥ 50 with no symptoms: DM but second test</p>
</li>
<li>
<p>41-49 (6.1-6.9) intermediate hyperglycaemia</p>
<ul>
<li>
<p>lifestyle</p>
</li>
<li>
<p>CVD risk</p>
</li>
<li>
<p>follow guidelines</p>
</li>
</ul>
</li>
<li>
<p>≤ 40 - DM unlikely</p>
</li>
</ul>
</li>
<li>
<p>fasting remains useful where HbA1c cannot be used</p>
<ul>
<li>
<p>fast for at least 8hrs; pref 12</p>
<ul>
<li>
<p>symptomatic</p>
<ul>
<li>≥ 7.0 (x1 if clear; x2 if borderline)</li>
</ul>
</li>
<li>
<p>asymptomatic</p>
<ul>
<li>
<p>≥ 7.0 strongly suggests but need another to confirm</p>
<ul>
<li>within 2/52</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>serum glucose levels risen too quickly</strong></p>
<ul>
<li>
<p>all children/adolescent suspected of T1DM</p>
</li>
<li>
<p>short duration of symptoms</p>
</li>
<li>
<p>at high risk of DM who are acutely unwell</p>
<ul>
<li>
<p>value \&lt; 50 odnes’t exclude</p>
</li>
<li>
<p>where as ≥50 confirms</p>
</li>
</ul>
</li>
<li>
<p>people taking medicines that cause rapid gluose rise for ≤ 2mo</p>
<ul>
<li>
<p>corticosteroids</p>
</li>
<li>
<p>antipsychotics</p>
</li>
</ul>
</li>
<li>
<p>acute pancreatic damage - who have had pancreatic surgery</p>
</li>
</ul>
</li>
<li>
<p><strong>condition affect accuracy of HbA1c</strong></p>
<ul>
<li>
<p>increased</p>
<ul>
<li>
<p>iron deficinency</p>
</li>
<li>
<p>vit b12 impairment</p>
</li>
<li>
<p>renal impairment</p>
</li>
<li>
<p>etoh</p>
</li>
<li>
<p>splenectomy</p>
</li>
<li>
<p>Vit C or E deficiency</p>
</li>
<li>
<p>CKD</p>
</li>
<li>
<p>Aspirin (large doses)</p>
</li>
<li>
<p>chronic opiate use</p>
</li>
<li>
<p>hydroxyurea</p>
</li>
</ul>
</li>
<li>
<p>Decreased</p>
<ul>
<li>
<p>iron/vitb12/folate supplementation</p>
</li>
<li>
<p>EPO</p>
</li>
<li>
<p>reticulocytosis</p>
</li>
<li>
<p>chronic liver disease</p>
</li>
<li>
<p>blood loss</p>
</li>
<li>
<p>splenoomegaly</p>
</li>
<li>
<p>RA</p>
</li>
<li>
<p>haemoglobinopathies</p>
</li>
<li>
<p>recent blood transfusion</p>
</li>
</ul>
</li>
<li>
<p>variable</p>
<ul>
<li>
<p>haemoglobinopathies</p>
</li>
<li>
<p>sickle cell</p>
</li>
<li>
<p>iron deficinecy anaemia</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>pregnant women = continue to use oral glucose tolerance test for GDM with abnormal polycose screen</p>
<ul>
<li>or who have been pregnant in last 2mo</li>
</ul>
</li>
<li>
<p>fructosamine = glycated protein that indicates glycation levels over preceding 14-21d</p>
</li>
<li>
<p>testing at any age considered beneficial</p>
</li>
</ul>
<h4 id="screening">Screening</h4>
<ul>
<li>
<p>aymptomatic men >45; women >55yo</p>
</li>
<li>
<p>Maori, pacific and indo asian -10yrs earlier</p>
</li>
<li>
<p>3-5 yrs based on risk</p>
</li>
<li>
<p>ten years earlier if;</p>
<ul>
<li>
<p>fhx of early onset T2DM</p>
</li>
<li>
<p>history gestational dm</p>
</li>
<li>
<p>known ischaemic heart disease, cerebrovascular disease, PVD</p>
</li>
<li>
<p>central obesity or BMI >30 (>27 indo-asian)</p>
</li>
<li>
<p>long term steroid or antipsychotic trematnet</p>
</li>
<li>
<p>intermediate hyperglycaemia on previous assessment</p>
</li>
<li>
<p>adverse lipid profile</p>
</li>
<li>
<p>high BP</p>
</li>
<li>
<p>PCOS</p>
</li>
<li>
<p>current smoker (or quit 12 months)</p>
</li>
</ul>
</li>
</ul>
<h3 id="management">management</h3>
<blockquote>
<p>good control known to delay onset of microvascular complications:</p>
<ul>
<li>
<p>renal failure</p>
</li>
<li>
<p>retinopathy</p>
</li>
<li>
<p>neuropathy</p>
</li>
</ul>
<p>also benefit for macrovascular if achieved early and maintained</p>
</blockquote>
<p><strong><em> Target = 50-55</em></strong></p>
<ul>
<li>
<p>existing complications;</p>
<ul>
<li>
<p>foot, eye, kidney, cvd</p>
<ul>
<li><strong>high risk category</strong></li>
</ul>
</li>
</ul>
<p><strong><em>Managed intensively</em></strong></p>
</li>
</ul>
<h4 id="determining-level-of-risk-for-dm-complications">Determining level of risk for DM complications</h4>
<ul>
<li>
<p>Low risk</p>
<ul>
<li>
<p>HbA1c 50-55</p>
</li>
<li>
<p>BP \&lt;130/80</p>
</li>
<li>
<p>ACR \&lt;2.5M, \&lt;3.5F</p>
</li>
<li>
<p>eGFR ≥60</p>
</li>
<li>
<p>Lipis: TAG \&lt;1.7, total cholesterol \&lt;4.0</p>
</li>
<li>
<p>non smoker</p>
</li>
<li>
<p>attends at least 6monthly review;</p>
<ul>
<li>
<p>HbA1c</p>
</li>
<li>
<p>BP</p>
</li>
</ul>
</li>
<li>
<p>annual review:</p>
<ul>
<li>
<p>lipids</p>
</li>
<li>
<p>ACR</p>
</li>
<li>
<p>eGFR</p>
</li>
<li>
<p>foot check</p>
</li>
</ul>
</li>
<li>
<p>2 yearly screening</p>
</li>
</ul>
</li>
<li>
<p>Moderate/high (high 3, moderate 2)</p>
<ul>
<li>
<p>HbA1c >55</p>
<ul>
<li>risk increases incrementally with increase hba1c</li>
</ul>
</li>
<li>
<p>BP ≥ 130/80</p>
</li>
<li>
<p>ACR ≥ 2.5 or ≥ 3.5</p>
</li>
<li>
<p>eGFR \&lt;60</p>
</li>
<li>
<p>Lipids;</p>
<ul>
<li>
<p>TAG >1.7</p>
</li>
<li>
<p>total cholesterol ≥4</p>
</li>
</ul>
</li>
<li>
<p>Current smoker</p>
</li>
<li>
<p>Ethincity</p>
</li>
<li>
<p>moderate reinopathy (R3, mild maculopathy (M3)</p>
</li>
<li>
<p>more than 1 year since DM last reviewed or poor adherence/attendence</p>
</li>
</ul>
</li>
</ul>
<h4 id="goals">Goals;</h4>
<ul>
<li>
<p><strong>lifestyle advice</strong></p>
<ul>
<li>
<p>dietary</p>
</li>
<li>
<p>exercise</p>
</li>
<li>
<p>ABC smoking cessation</p>
</li>
</ul>
</li>
<li>
<p><strong>Medication adjustment/intensification</strong></p>
<ul>
<li>
<p>improve hylcaemic control - HbA1c 50-55 as individually agreed</p>
</li>
<li>
<p>control BP - \&lt;130/80</p>
<ul>
<li>
<p>\&lt;120 = greater frequency of serious adverese effects</p>
<ul>
<li>ACCORD 2010</li>
</ul>
</li>
</ul>
</li>
<li>
<p>lipid control - TAG \&lt;1.7, total \&lt;4Th</p>
</li>
</ul>
</li>
<li>
<p><strong>Ongoing clinical reveiw</strong></p>
<ul>
<li>
<p>monitor BP, HbA1c, eGFR 3 monthly</p>
</li>
<li>
<p>ACR 6 monthly</p>
</li>
<li>
<p>Annually</p>
<ul>
<li>
<p>weight </p>
</li>
<li>
<p>peripehral neurovascular status</p>
</li>
<li>
<p>cardiovascualr status</p>
</li>
<li>
<p>feet 3mo if complications</p>
</li>
</ul>
</li>
<li>
<p>2 yearly</p>
<ul>
<li>retinopathy</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="lifestyle">Lifestyle</h4>
<ul>
<li>
<p>Diet</p>
<ul>
<li>
<p>Glycaemic load vs. glycaemic index</p>
<ul>
<li>
<p>(carbohydrate x GI)/100</p>
</li>
<li>
<p>Glycaemic index = rate at whcih glucose released into blood stream</p>
</li>
<li>
<p>low: carrots, apples, watermelon, peanuts, kidney beans, chick peas, lentil, spop corn</p>
</li>
<li>
<p>medium: banana, new potato, kumara, jioce</p>
</li>
<li>
<p>high: pasta, cous cous whiete rice</p>
</li>
</ul>
</li>
<li>
<p>fibre</p>
<ul>
<li>
<p>only soluable (fruit, vege, legumes, oats) affect glycaemic control</p>
</li>
<li>
<p>increase viscosity and stomach/bowel take longer to empty</p>
</li>
<li>
<p>25g/d W, 30g/d adult men</p>
</li>
</ul>
</li>
<li>
<p>carbohydrate counting</p>
<ul>
<li>
<p>type 1</p>
</li>
<li>
<p>match insulin dose to intake</p>
</li>
<li>
<p>15g carbohydrate (one slice bread…)</p>
</li>
</ul>
</li>
<li>
<p>diabetic/low sugar foods</p>
<ul>
<li>
<p>not necessary</p>
</li>
<li>
<p>more i mprotant to understand label</p>
</li>
<li>
<p>may still be high in kJ and fat</p>
</li>
<li>
<p>“no added sugar” doens’t mean no sugar</p>
</li>
<li>
<p>sugar free may still affect blood glucose</p>
</li>
<li>
<p>fructoes often used</p>
</li>
<li>
<p>lower GI</p>
<ul>
<li>requires less insulin than sucrose</li>
</ul>
</li>
<li>
<p>fructose may affect TAG and LDL</p>
<ul>
<li>
<p>soft drinks, canned fruits,</p>
</li>
<li>
<p>linked with complications of insulin resistance </p>
</li>
</ul>
</li>
<li>
<p>honey == table sugar</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Exercise</p>
<ul>
<li>
<p>walking :</p>
<ul>
<li>
<p>increase weight loss</p>
</li>
<li>
<p>improve glycaemic control</p>
</li>
<li>
<p>reduce cardiovascular mortality</p>
</li>
<li>
<p>NNT to prevent 1 death with 2 hrs/week wlaking</p>
<ul>
<li><strong>61</strong></li>
</ul>
</li>
<li>
<p>compared to NNT metformin = <strong>141</strong></p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Self monitoring</p>
<ul>
<li>
<p>benefits</p>
<ul>
<li>
<p>assisting patients and health practitionsers in ajustment of insulin or other medication</p>
</li>
<li>
<p>encouraging self-empowerment</p>
</li>
<li>
<p>promoting better self-management behaviours</p>
</li>
</ul>
</li>
<li>
<p>negatives</p>
<ul>
<li>may fail to improve diabetes</li>
</ul>
</li>
<li>
<p>recommended:</p>
<ul>
<li>
<p>insulin - YES</p>
</li>
<li>
<p>metformin and other oral: NOT but…</p>
<ul>
<li>
<p>at increase risk of hypoglycaemia</p>
</li>
<li>
<p>experiencing acute illness</p>
</li>
<li>
<p>undergoing signiicant changes in pharmacotherpay or fasting</p>
</li>
<li>
<p>unstable or poor glycaemic control</p>
<ul>
<li>HbA1c >64</li>
</ul>
</li>
<li>
<p>pregnant/planning pregnancy</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="metformin">Metformin</h4>
<ul>
<li>
<p>expected HbA1c reduction: 12-22</p>
</li>
<li>
<p>first line for all people</p>
</li>
<li>
<p>decreases glucose formation in liver and increase peripheral utilisation of glucose</p>
</li>
<li>
<p>particularly effective if overwieght</p>
</li>
<li>
<p>may confer cardiovascualr protection beyond glucose lowering</p>
</li>
<li>
<p>start low dose to avoid initial GI upset:</p>
<ul>
<li>
<p><strong>500mg od</strong> or 250mg od</p>
</li>
<li>
<p>total daily dose shouln’t exceed 2g</p>
</li>
</ul>
</li>
<li>
<p>adverse effects</p>
<ul>
<li>
<p>diarrhoea - usually transient</p>
</li>
<li>
<p><em>taste distrubance</em></p>
</li>
<li>
<p>(decrease vit B12 abdorption)</p>
</li>
<li>
<p>rarely lactic acidosis</p>
<ul>
<li>
<p>feature of AKI and acute cardiac / respiratoyr failure</p>
</li>
<li>
<p>in association with CKD</p>
</li>
<li>
<p>if illness -> dehydration: temporarily cease taking metformin</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>reduced in patients with eGFR 30-60 (max 1g)</p>
</li>
<li>
<p>not begun with significant renal impairment (efGR \&lt;30)</p>
</li>
</ul>
<h4 id="sulfonylurea">sulfonylurea</h4>
<ul>
<li>
<p>expected HbA1c reduction: 15-20</p>
</li>
<li>
<p>add if haven’t reached agreed HbA1c target after 3 months</p>
</li>
<li>
<p>increase insulin secretion if patient has functional pancreatic beta cells</p>
<ul>
<li>
<p>canc ause hypoglycaemia and weight gain</p>
<ul>
<li>avoid in severe hepatic and renal impairment</li>
</ul>
</li>
</ul>
</li>
<li>
<p>contraindicated in patients with ketoacidosis</p>
</li>
<li>
<p>avoided with acute prophyria</p>
</li>
<li>
<p>shorter acting:</p>
<ul>
<li>
<p><strong>glipizide</strong></p>
<ul>
<li>
<p>2.5-5mg daily with or shortly before breakfast or lunch</p>
</li>
<li>
<p>adjust dose according to response by 2.5-5mg daily at weekly intervals</p>
</li>
<li>
<p>usual maintenece = 2.5-30</p>
</li>
<li>
<p>maximum 40mg daily</p>
</li>
<li>
<p>no more than 15mg in single dose</p>
</li>
</ul>
</li>
<li>
<p><strong>gliclazide</strong></p>
<ul>
<li>
<p>40mg with breakfast</p>
</li>
<li>
<p>up to 160mg single dose</p>
</li>
<li>
<p>maximum 320mg daily</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>longer acting:</p>
<ul>
<li>
<p><strong>glibenclamide</strong></p>
<ul>
<li>
<p>2.5-5mg daily </p>
</li>
<li>
<p>adjust according to response by 2.5mg daily every 1-2wks</p>
</li>
<li>
<p>maximum 10mg as single dose</p>
</li>
<li>
<p>maximum 15mg daily</p>
</li>
<li>
<p>not recommended older adult</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="insulin">Insulin</h4>
<ul>
<li>
<p>eventually required</p>
</li>
<li>
<p>early intiiation can be appropriate</p>
<ul>
<li>beta cell function declines linearly and after 10 years 50% people will require insulin</li>
</ul>
</li>
<li>
<p>shoudn’t be delayed in patients with poor glycaemic control</p>
</li>
<li>
<p>result in development of long-term complciations</p>
</li>
<li>
<p>discuss fears/personal failing</p>
<ul>
<li>
<p>insulin = most effective glucose lowering medicine</p>
</li>
<li>
<p>half of patients with T2DM reported to eventually require insulin to achieve good glycaemic control</p>
</li>
</ul>
</li>
<li>
<p>women with T2DM who become pregnant almost always require initiation of insulin</p>
</li>
<li>
<p>any person with T2DM where HbA1c not close to previously agreed target or symptoms of hyperglycaemia despinte</p>
<ul>
<li>
<p>approriate focus on diet, phsycial exercies, behavioural strategies and other lifestyle interventions</p>
</li>
<li>
<p>appropriate compliance with and odse optimisation of oral hypoglycaemic medicines</p>
</li>
</ul>
</li>
<li>
<p>general rule:</p>
<blockquote>
<ul>
<li>>65mmol/mol</li>
</ul>
</blockquote>
<ul>
<li>
<p>consideration</p>
<ul>
<li>
<p>age</p>
</li>
<li>
<p>presence of symptoms</p>
</li>
<li>
<p>long term risk of complications</p>
</li>
<li>
<p>ability to manage insulin treatment</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<h5 id="analogues-of-insulin">analogues of insulin:</h5>
<ul>
<li>
<p>isophane</p>
<ul>
<li>
<p>first line for T2DM</p>
</li>
<li>
<p>intermediate acting</p>
</li>
<li>
<p>maximal effect 4-12hrs</p>
</li>
<li>
<p><strong>Protaphane</strong></p>
</li>
<li>
<p><strong>Humulin NPH</strong></p>
</li>
<li>
<p>once daily:</p>
<ul>
<li>
<p>start at 8-10U before meal</p>
</li>
<li>
<p>titrate:</p>
<ul>
<li>
<p>BSL >8 and never \&lt;4:</p>
<ul>
<li>increase 4-6U</li>
</ul>
</li>
<li>
<p>BSL 6-8 and never \&lt;4</p>
<ul>
<li>increase 2-4U</li>
</ul>
</li>
<li>
<p>once >20 and 3 fasting over target and blood glucose never \&lt;4</p>
<ul>
<li>increase 10-20%</li>
</ul>
</li>
</ul>
</li>
<li>
<p>at night if pre=breakfast high</p>
<ul>
<li>alert for symptoms of nocturnal hypoglycaemia with doses >20U</li>
</ul>
</li>
<li>
<p>before breakfast if daytime hyperglycaemia</p>
</li>
</ul>
</li>
<li>
<p>metformin and sulphonylurea should continue</p>
</li>
<li>
<p>if bd dosing:</p>
<ul>
<li>
<p>if high blood glucose during day and night or HbA1c >75</p>
</li>
<li>
<p>start with 6-10U bd before meals</p>
</li>
<li>
<p>sulphonyluea should cease</p>
</li>
<li>
<p>titrate:</p>
<ul>
<li>
<p>Prebreakfast:</p>
<ul>
<li>
<p>>8 and never \&lt;4</p>
<ul>
<li>increase night dose by 4-5</li>
</ul>
</li>
<li>
<p>6-8 and never \&lt;4</p>
<ul>
<li>increase night dose by 2-4</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Preevening</p>
<ul>
<li>
<p>generally >8 and never \&lt;4</p>
<ul>
<li>increase pre-breakfast 4-5</li>
</ul>
</li>
<li>
<p>7-8 and never \&lt;4</p>
</li>
</ul>
</li>
<li>
<p>once >20u change by 10-20% of <strong>daily</strong> dose</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Basal insulin analgoues</p>
<ul>
<li>
<p><strong>glargine</strong></p>
<ul>
<li>
<p>given morning or night where hypoglycaemia is a concern</p>
</li>
<li>
<p>titrated to normalise pre-breakfast glucose levesl</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Premixed insulin</p>
<ul>
<li>
<p>fixed ratio of hsort and intermediate</p>
</li>
<li>
<p>given 1 or 2 /day</p>
</li>
<li>
<p>already taking insulin has conssitently hgih blood glucose follwoing meals and where HbA1c targets not being met</p>
</li>
<li>
<p>not intiiated</p>
</li>
</ul>
</li>
<li>
<p>seek advice</p>
<ul>
<li>
<p>child / adolescent</p>
</li>
<li>
<p>very lean or has lost weight rapidly</p>
<ul>
<li>glutamic acid decarboxylast autoantibodies: indicate T1DM</li>
</ul>
</li>
<li>
<p>repeated hypoglycaemia</p>
</li>
<li>
<p>vocational driver</p>
</li>
<li>
<p>HbA1c remain above target following insulin initiation and titration</p>
</li>
</ul>
</li>
<li>
<p>twice weekly phone-calls recommended with face-face as required to begin with</p>
</li>
<li>
<p>one month after initiation</p>
</li>
<li>
<p>medication not substitute for healthy lifestyle, smoking,….</p>
</li>
<li>
<p>Self monitoring of blood glucose</p>
<ul>
<li>
<p>should be performed for approximately one week prior to deciding which insulin regime a patient would benefit from the most</p>
</li>
<li>
<p>before each meal and ideally 2hrs after evening meal and breakfast</p>
</li>
<li>
<p>strips</p>
<ul>
<li>4 tests/day for 3mo</li>
</ul>
</li>
</ul>
</li>
<li>
<p>needles can be used up to four times</p>
</li>
<li>
<p>ensure patient knows:</p>
<ul>
<li>
<p>name of insulin they have been prescribed</p>
</li>
<li>
<p>correct dose</p>
</li>
<li>
<p>whether insulin is short, intermediate, long-acting or premixed</p>
</li>
<li>
<p>what cartridge/vial size they need</p>
</li>
<li>
<p>how to correctly match their insulin with required delivery device</p>
</li>
</ul>
</li>
<li>
<p>minimize prescription error:</p>
<ul>
<li>
<p>use brand name</p>
</li>
<li>
<p>infomr patient details</p>
</li>
<li>
<p>ensure any changes explained and clearly understood</p>
</li>
</ul>
</li>
<li>
<p>storage</p>
<ul>
<li>
<p>door of fridge</p>
</li>
<li>
<p>stored @ room temperature for up to 28d</p>
</li>
<li>
<p>pen (3mL), syringe (10mL)</p>
</li>
<li>
<p>needle 5-8mm and fine (31g)</p>
</li>
</ul>
</li>
</ul>
<h4 id="acarbose">Acarbose</h4>
<ul>
<li>
<p>alpha-Glucosidase inhibitor</p>
</li>
<li>
<p>expected HbA1c reduction: 6-11</p>
</li>
<li>
<p>safe and mildly effective</p>
</li>
<li>
<p>reduces amount of glucose absorbed in small intestine</p>
<ul>
<li>
<p>blocking alpha-glucosidase enzyme</p>
<ul>
<li>N) breaks down complex carbohydrates into glucose</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Most effective for relieving post prandial hyperglycaemia</p>
<ul>
<li>significant contributor to cardiovascualr disease and the microvascular complications of T2DM</li>
</ul>
</li>
<li>
<p>little effect on fasting levels</p>
</li>
<li>
<p>doesn’t increase risk of hypoglycaemia</p>
</li>
<li>
<p>when used in combination - enhances hypoglycaemic effect</p>
</li>
<li>
<p>start <strong>50mg tds</strong> chewed and swallowed with water immediately before eating or with first mouthful</p>
</li>
<li>
<p>increase 100mg tds after 4-8wks</p>
</li>
<li>
<p>maximum - 200mg tds</p>
</li>
<li>
<p>adverse effects</p>
<ul>
<li>
<p>flatulence in 3/4</p>
</li>
<li>
<p>soft stool and diarrhoea</p>
</li>
<li>
<p>hepatitis reported</p>
</li>
</ul>
</li>
<li>
<p>CI </p>
<ul>
<li>
<p>pregnancy</p>
</li>
<li>
<p>hepatic/renal impairment (CKD4)</p>
</li>
<li>
<p>IBD</p>
</li>
<li>
<p>previous abdominal surgery</p>
</li>
<li>
<p>GI disorder with malabsorption</p>
</li>
</ul>
</li>
</ul>
<h4 id="glitazones-pioglitazone">Glitazones (pioglitazone)</h4>
<ul>
<li>
<p>classified as insulin sensitisers</p>
<ul>
<li>increase body’s ability to transport glucose across cell membranes</li>
</ul>
</li>
<li>
<p>don’t cause hypoglyceamia</p>
</li>
<li>
<p>associated with:</p>
<ul>
<li>
<p><strong>heart failure</strong></p>
<ul>
<li>increase fluid retention</li>
</ul>
</li>
<li>
<p>bladder cancer</p>
</li>
<li>
<p>increase risk of bone fractures</p>
</li>
</ul>
</li>
<li>
<p>Pioglitasone only prep available in NZ</p>
<ul>
<li>
<p>special authority</p>
</li>
<li>
<p>already taking max doses of metformin or sulfonylurea or where one or both CI or not toleraited or insulin not achieved glycaemic control</p>
</li>
</ul>
</li>
<li>
<p>started if:</p>
<ul>
<li>
<p>second line metformin if hba1c >50 or > target and person at significant risk of hypoglycameia or its consequences</p>
</li>
<li>
<p>second line to firstline sulfonylurea if hba1c >50 and patient doens’t tolerate/CI metformin</p>
</li>
<li>
<p>3rd line if hba1c >59 and insulin neither appropriate or unacceptable</p>
</li>
<li>
<p>combination with insulin if taking high dose insulin and not responded</p>
</li>
</ul>
</li>
<li>
<p>initiate</p>
<ul>
<li>
<p>15-50mg od</p>
</li>
<li>
<p>concurrent use increase risk of hypoglycaemia</p>
</li>
</ul>
</li>
<li>
<p>only continue if hba1c reduced 5mmol/mol</p>
</li>
<li>
<p>associated with weight gain</p>
</li>
</ul>
<h4 id="glp-1-glucagon-like-peptide-1-agonists">GLP-1 (glucagon-like peptide 1) agonists</h4>
<ul>
<li>
<p>mimic endogenous incretins</p>
<ul>
<li>peptides with short half-lives secreted from gut following a meal</li>
</ul>
</li>
<li>
<p>enhances endogenous secretion of insulin following eating</p>
</li>
<li>
<p>inhibits glucagon secretion</p>
</li>
<li>
<p>suppress appetite and food intake</p>
</li>
<li>
<p>associated with weight loss in overweight or obese people with or without T2DM</p>
</li>
<li>
<p>increase likelihood of pancreatitis x2</p>
</li>
<li>
<p><strong>Exenatide</strong> (subcut)</p>
<ul>
<li>
<p>approved but not subsideised</p>
</li>
<li>
<p>third line</p>
<ul>
<li>
<p>bmi ≥ 35</p>
</li>
<li>
<p>or bmi \&lt;35 and insulin inappropriate</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="surgical-intervention">Surgical intervention</h4>
<ul>
<li>
<p>effective</p>
</li>
<li>
<p>BMI >35</p>
<ul>
<li>when lifestyle and mediicnes ineffective</li>
</ul>
</li>
<li>
<p>NNT diabetes remission @ 2yr follow-up 1.3 (gastric bypass) 1.0 (biliopancreatic diversion)</p>
</li>
<li>
<p>how long can maintain this level of glycameic control?????</p>
</li>
</ul>
<h3 id="complications">Complications</h3>
<h4 id="diabetic-peripheral-neuropathy">diabetic peripheral neuropathy</h4>
<ul>
<li>
<p>see page: neurology</p>
</li>
<li>
<p>risk factors;</p>
<ul>
<li>
<p>PVD</p>
<ul>
<li>
<p>smoking</p>
</li>
<li>
<p>htn</p>
</li>
<li>
<p>hypercholesterolaemia</p>
</li>
</ul>
</li>
<li>
<p>peripheral neuropahty</p>
</li>
<li>
<p>previosu amputaiton</p>
</li>
<li>
<p>previous ulceration</p>
</li>
<li>
<p>presence of callus</p>
</li>
<li>
<p>joint deformity</p>
</li>
<li>
<p>visual/mobility problems</p>
</li>
</ul>
</li>
</ul>
<h4 id="hypertension">Hypertension</h4>
<ul>
<li>
<p>targe \&lt;130/80</p>
<ul>
<li>
<p>\&lt;120= increased adverse events</p>
</li>
<li>
<p>reduce salt by 1 teaspoon/day = 5g = 5mmHg drop in sBP</p>
</li>
</ul>
</li>
</ul>
<h4 id="renal-disease">Renal disease</h4>
<ul>
<li>
<p>Microalbuminuria (ACR >2.5M or >3.5F) earilest sign of diabetic kidney disease</p>
</li>
<li>
<p>ACEi/ARB recommended for patients with T2DM and microalbuminauria regardless of whether HTN present</p>
</li>
<li>
<p>DM and ACR > 30 on 2 occasions = 5yr CVRA >20%</p>
</li>
</ul>
<h4 id="diabetic-retinopathy">Diabetic retinopathy</h4>
<ul>
<li>
<p>one of leading causes of blindness and vision impairment</p>
</li>
<li>
<p>30% with DM some degree of retinopathy</p>
<ul>
<li>10% sight threatening</li>
</ul>
</li>
<li>
<p>longer duration DM -> greater prevalence</p>
</li>
<li>
<p>asymptomatic until @ advanced stage</p>
</li>
<li>
<p>referral for regualr retinal screening at least every 2 yrs</p>
</li>
<li>
<p>screening</p>
<ul>
<li>
<p>Type 1:</p>
<ul>
<li>
<p>1st = 5 yrs after diagnosis or after puberty</p>
</li>
<li>
<p>2 yearly</p>
</li>
</ul>
</li>
<li>
<p>Type 2 DM</p>
<ul>
<li>
<p>soon as possible</p>
</li>
<li>
<p>2 yearly</p>
</li>
</ul>
</li>
<li>
<p>Pregnancy + DM</p>
<ul>
<li>
<p>first trimester</p>
</li>
<li>
<p>2 yearly</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Management</p>
<ul>
<li>
<p>duration = most signifiant risk factor</p>
<ul>
<li>
<p>poor glycaemic control also major contributor</p>
</li>
<li>
<p>htn</p>
</li>
<li>
<p>nephropathy</p>
</li>
</ul>
</li>
<li>
<p>maintain good glycaemic control</p>
</li>
<li>
<p>manage htn</p>
</li>
<li>
<p>advise re healthy lifestyle</p>
</li>
<li>
<p>blood lipidd</p>
</li>
</ul>
</li>
<li>
<p>non proliferative retinopathy</p>
<ul>
<li>
<p>microaneurysms</p>
</li>
<li>
<p>haemorrhages</p>
<ul>
<li>
<p>dot and blot (deeper) - more common in dm</p>
</li>
<li>
<p>flame = htn</p>
</li>
</ul>
</li>
<li>
<p>hard exudates - leake of srum proteins</p>
</li>
<li>
<p>cotton wool spots - right angles to direction of nerve fibre</p>
</li>
<li>
<p>macular oedema</p>
</li>
<li>
<p>venous loops and beading</p>
</li>
</ul>
</li>
<li>
<p>proliferative</p>
<ul>
<li>
<p>restricted blood supply -> VGEF -> neovascularisation</p>
</li>
<li>
<p>fragile and easily broken</p>
</li>
<li>
<p>fibrous tissue formed</p>
<ul>
<li>traction = retinal oedema, tears and detachment</li>
</ul>
</li>
</ul>
</li>
</ul>
<h3 id="hypoglycaemia">Hypoglycaemia</h3>
<ul>
<li>
<p>when bsl \&lt;4</p>
</li>
<li>
<p>most common causes:</p>
<ul>
<li>
<p>lack of food</p>
</li>
<li>
<p>increase physical activity</p>
</li>
<li>
<p>administration of insulin or less commonly sulphonylurea</p>
</li>
<li>
<p>consumptoin of etoh without food</p>
</li>
</ul>
</li>
<li>
<p>symptoms;</p>
<ul>
<li>
<p>hunger</p>
</li>
<li>
<p>blurred vision</p>
</li>
<li>
<p>headache</p>
</li>
<li>
<p>light headedness</p>
</li>
<li>
<p>loss of concentration, confusion, irritability</p>
</li>
<li>
<p>sweating, tingling around mouth and lips, trembling, weaknes,s possible loss of conciousness</p>
</li>
</ul>
</li>
<li>
<p>management:</p>
<ul>
<li>
<p>check blood glucose</p>
</li>
<li>
<p>10-15g glucose</p>
<ul>
<li>
<p>6 jelly beans, 2-3 glucose tables</p>
</li>
<li>
<p>small glass soft drink (sugar)</p>
</li>
</ul>
</li>
<li>
<p>5-10min repeat blood glucose</p>
</li>
<li>
<p>should continue until over 4.0</p>
<ul>
<li>eat small meal / snack</li>
</ul>
</li>
<li>
<p>report episodes of hypoglycaemia</p>
</li>
</ul>
<p>- </p>
</li>
</ul>
<h3 id="referral">referral</h3>
<ul>
<li>
<p>previous cardiac event/stroke/tia</p>
</li>
<li>
<p>eGFR \&lt;45 and / or ACR >30</p>
</li>
<li>
<p>severe retinopathy or moderate maculopathy in either eye</p>
</li>
<li>
<p>previous amputation/ulceration</p>
</li>
<li>
<p>peripehral arterial disease/previous leg vascular disease</p>
</li>
</ul>
<h3 id="follow-up">follow - up</h3>
<ul>
<li>
<p>at least annually</p>
</li>
<li>
<p>should involve</p>
<ul>
<li>
<p>HbA1c</p>
</li>
<li>
<p>blood pressure</p>
</li>
<li>
<p>lipid levels</p>
</li>
<li>
<p>assessment of DM related complications</p>
<ul>
<li>
<p>CVD</p>
</li>
<li>
<p>kidney disease</p>
</li>
<li>
<p>foot checks</p>
</li>
<li>
<p>retinal complications</p>
</li>
</ul>
</li>
<li>
<p>eucation</p>
</li>
</ul>
</li>
</ul>
<h3 id="poor-glycaemic-control-hba1c-6264mmolmol">Poor glycaemic control HbA1c >64mmol/mol</h3>
<ul>
<li>
<p>relatively common</p>
</li>
<li>
<p>numerous reasons</p>
</li>
<li>
<p>may be appropriate</p>
</li>
<li>
<p>individual approach</p>
<ul>
<li>
<p>target-based approach may be harmful</p>
<ul>
<li>older patients with high cardiovascular risk</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Patients beliefs</p>
<ul>
<li>
<p>Disease identity</p>
</li>
<li>
<p>cause of type 2 DM</p>
<ul>
<li>belief that just inherited from parents</li>
</ul>
</li>
<li>
<p>Timeline</p>
<ul>
<li><strong>what is course and how long will it last</strong></li>
</ul>
</li>
<li>
<p>consequences of type 2 dm</p>
<ul>
<li><strong>belief that introducing insulin means you are going to die soon</strong></li>
</ul>
</li>
<li>
<p>Cure/control</p>
<ul>
<li><strong>how well the patient will be able to recover from and control their dm</strong></li>
</ul>
</li>
</ul>
</li>
<li>
<p>strength of patient’s belief in ability to influence own health = predictor for adherence to phsyical activity and life satisfaction</p>
</li>
<li>
<p>medications influenced by:</p>
<ul>
<li>
<p>fear</p>
</li>
<li>
<p>fatalistic acceptance of disease</p>
</li>
<li>
<p>family/whanau’s negative experience with treatment</p>
</li>
</ul>
</li>
<li>
<p>What matters to the patient:</p>
<ul>
<li>
<p><strong>how important quality of life</strong></p>
</li>
<li>
<p><strong>how motivated to prevent diabetes-related complications</strong></p>
</li>
<li>
<p><strong>patients attitude towards insulin and self-injection</strong></p>
</li>
<li>
<p><strong>is patient concerned about hypoglycaemia</strong></p>
</li>
</ul>
</li>
</ul>
<h3 id="intermediate-hyperglycaemia">Intermediate hyperglycaemia</h3>
<ul>
<li>
<p>don’t need confirmatory testing if patient is well</p>
</li>
<li>
<p>5-10% progress to DM/year - 70% total</p>
<ul>
<li>
<p>RR 6</p>
<ul>
<li>compared to normoglycaemia</li>
</ul>
</li>
<li>
<p>risk increased</p>
<ul>
<li>
<p>age</p>
</li>
<li>
<p>weight/bmi</p>
</li>
<li>
<p>physical activity</p>
</li>
<li>
<p>diet </p>
</li>
<li>
<p>ethnicity - Maori, pacific , south asia</p>
</li>
<li>
<p>smoking</p>
</li>
<li>
<p>fhx diabetes</p>
</li>
<li>
<p>increase blood pressure</p>
</li>
<li>
<p>increase lipid</p>
</li>
<li>
<p>PCOS</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>viewed as continuous scale</p>
</li>
<li>
<p>many vasuclar complications begin before hba1c reaches diabetic levels</p>
<ul>
<li>
<p>nephropathy</p>
</li>
<li>
<p>CKD</p>
</li>
<li>
<p>neuropathy</p>
</li>
<li>
<p>retinopathy</p>
</li>
<li>
<p>cardiovascular disease</p>
</li>
<li>
<p>overall mortality</p>
</li>
</ul>
</li>
</ul>
<h4 id="management_1">management</h4>
<ul>
<li>
<p>reduce progression to DM - 30-60% decrease</p>
<ul>
<li>
<p>lifestyle changes</p>
<ul>
<li>NNT 6.9</li>
</ul>
</li>
<li>
<p>initian of metformin wehre appropriate</p>
<ul>
<li>
<p>NNT 13.9</p>
</li>
<li>
<p>>60 </p>
</li>
<li>
<p>lower body mass index</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>agree on target HbA1c </p>
<ul>
<li>
<p>\&lt;40</p>
</li>
<li>
<p>repeat test 6/12 - 12/12</p>
</li>
</ul>
</li>
<li>
<p>lifestyle</p>
<ul>
<li>
<p>everyone</p>
</li>
<li>
<p>150min moderate exercise</p>
</li>
<li>
<p>gradually lose weight</p>
</li>
<li>
<p>increase consumptino of whole grains, vegetables and other foods high in dietary fibre</p>
</li>
<li>
<p>reduce total amount of fat</p>
</li>
<li>
<p>eat less saturated fat</p>
</li>
<li>
<p>key componenets of effective lifestyle programme</p>
<ul>
<li>
<p>meet 8 times over 9-19mo</p>
</li>
<li>
<p>at least 16hrs educational time - group or 1:1</p>
</li>
<li>
<p>follow-up sessions regularly</p>
</li>
<li>
<p>behavioural change techniques used in conjunction with diet and exercise advice</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Add metformin if lifestyle not benefit in 6/12</p>
<ul>
<li>500mg od</li>
</ul>
</li>
</ul>
      </div>
    </div>

  </div>
    

    <div class="footer">
        <p>Website powered by <a href="http://urubu.jandecaluwe.com">Urubu</a></p>
    </div>


</div> 


    <!-- jQuery (necessary for Bootstrap's JavaScript plugins) -->
    <script src="https://code.jquery.com/jquery.js"></script>
    <!-- Include all compiled plugins (below), or include individual files as needed -->
    <script src="//netdna.bootstrapcdn.com/bootstrap/3.2.0/js/bootstrap.min.js"></script>

  </body>
</html>
